First-Line Nivolumab Plus Chemotherapy and Nivolumab Plus Ipilimumab Continue to Demonstrate OS Benefit in Patients with Advanced Oesophageal Squamous Cell Carcinoma By Ogkologos - September 1, 2026 70 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the 5-year follow-up of the CheckMate 648 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR Efficacy of Afamitresgene Autoleucel for HLA-A*02-positive and MAGE-A4-positive Synovial Sarcoma Following... April 2, 2024 A real Eureka moment for translation February 10, 2023 Picking out the sound of tumours June 18, 2020 Revumenib Shows Promise in Treating Advanced Acute Myeloid Leukemia April 18, 2023 Load more HOT NEWS A Combination of Avutometinib Plus Defactinib Results in Clinically Meaningful Benefit... Teclistamab Shows Promise for People with Heavily Pretreated Multiple Myeloma Sugar Compound Found in Breast Milk May Help Ease Chemotherapy Side... Targeted Therapy Cabozantinib Slows Progression of Rare Kidney Cancer
